Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg significantly improves health-related quality of life (HRQoL) utility scores compared to placebo in patients with obesity or overweight with comorbidities, with effects driven by both improvements in the treatment group and declines in the placebo group.
If you have obesity or overweight with related health issues, taking semaglutide 2.4 mg once a week along with lifestyle changes can significantly improve how you feel about your health compared to doing nothing. This improvement is seen in both those who take the drug and those who don't, as the drug helps maintain health while the placebo group's health utility tends to drop. The benefits include better physical functioning and overall quality of life.
Semaglutide 2.4 mg was associated with improvement in health utility scores compared with placebo, reaching statistical significance in STEP 1, 2 and 4.
Why this rating
Based on four large-scale, double-blind, randomized controlled trials (STEP 1-4) with rigorous statistical analysis.
Source
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials
Jakob Bue Bjørner et al. · Diabetes Obesity and Metabolism · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →